Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles

June 29, 2025

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and rectifying perverse financial incentives within health care contract structures.

The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings

September 4th 2024

By Skylar Jeremias

Article

A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.

Upcoming Biosimilars and the Impact of IRA: Key Takeaways From Jeffrey Casberg

September 3rd 2024

By Cameron Santoro

Article

Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and the evolving role of pharmacy benefit managers in the market.

Biosimilar Uptake Lags in US Despite Potential Cost Savings

September 2nd 2024

By Cameron Santoro

Article

Delayed biosimilar uptake in the US is driven by payer, provider, and patient barriers, but targeted interventions can help boost utilization and savings.

Biosimilars Business Roundup for August 2024—Podcast Edition

September 1st 2024

By Skylar Jeremias

Article

On this episode of Not So Different, the end of the second quarter brings with it expense reports, new biosimilar business deals, and insights into how federal policy impacts biosimilar company pursuits.

Biosimilars Business Roundup: August 2024

August 31st 2024

By Skylar Jeremias

Article

With the end of the second quarter comes expense reports, new biosimilar business deals, and insights into how federal policy impacts biosimilar company pursuits.

The Top 5 Biosimilar Articles for the Week of August 26

August 30th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 26, 2024.

Prioritizing Patient-Centered Care in PsA: Key Insights From the 2023 EULAR Guidelines

August 29th 2024

By Skylar Jeremias

Article

The 2023 European Alliance of Associations for Rheumatology (EULAR) recommendations for psoriatic arthritis (PsA) provide an evidence-based treatment strategy, prioritizing conventional and biological disease-modifying antirheumatic drugs, including biosimilars, tailored to disease manifestations, with an emphasis on safety, cost-effectiveness, and patient-centered care.

The Economic Impact of Etanercept Biosimilar Remonopolization in Poland

August 28th 2024

By Skylar Jeremias

Article

Market remonopolization by a biosimilar drug in Poland led to significant price increases for etanercept, resulting in over €3.42 million in excess health care costs, according to a recent study.

Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024

August 27th 2024

By Skylar Jeremias

Article

Sandoz’ earnings report for the first half of 2024 revealed 29% growth in biosimilar revenue, as well as a 7% increase in net sales, showcasing the value of biosimilars for biopharmaceutical manufacturers.

BioRationality: FDA Opens Up Biosimilar Inquiries on Reddit

August 26th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, urges stakeholders to engage with the FDA on its Reddit forum—where a representative will answer complex biosimilar questions—encourages clearing misconceptions, and advocates for updates to the Biologics Price Competition and Innovation Act guidelines.